Danaher Co. (NYSE:DHR) Shares Sold by First Commonwealth Financial Corp PA

First Commonwealth Financial Corp PA lowered its position in Danaher Co. (NYSE:DHR) by 1.1% in the third quarter, Holdings Channel.com reports. The firm owned 9,788 shares of the conglomerate’s stock after selling 110 shares during the quarter. Danaher makes up about 0.7% of First Commonwealth Financial Corp PA’s holdings, making the stock its 24th largest position. First Commonwealth Financial Corp PA’s holdings in Danaher were worth $2,721,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in DHR. CarsonAllaria Wealth Management Ltd. purchased a new stake in Danaher in the 2nd quarter worth approximately $25,000. nVerses Capital LLC purchased a new stake in Danaher in the 2nd quarter worth approximately $25,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Danaher in the 3rd quarter valued at $40,000. MFA Wealth Advisors LLC acquired a new position in shares of Danaher in the 2nd quarter valued at $51,000. Finally, Financial Connections Group Inc. acquired a new position in shares of Danaher in the 2nd quarter valued at $51,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Up 0.7 %

Shares of NYSE DHR traded up $1.55 during mid-day trading on Wednesday, reaching $238.13. The company had a trading volume of 150,873 shares, compared to its average volume of 2,755,588. Danaher Co. has a twelve month low of $215.68 and a twelve month high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The stock has a market capitalization of $172.00 billion, a PE ratio of 45.14, a price-to-earnings-growth ratio of 4.37 and a beta of 0.85. The stock’s 50 day moving average is $256.66 and its 200-day moving average is $259.81.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the business posted $2.02 earnings per share. The business’s quarterly revenue was up 3.1% on a year-over-year basis. As a group, equities analysts anticipate that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is presently 20.61%.

Analysts Set New Price Targets

A number of brokerages have commented on DHR. TD Cowen boosted their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a report on Thursday, October 31st. UBS Group dropped their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Stifel Nicolaus boosted their target price on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Finally, Barclays lowered their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $287.16.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.